<DOC>
	<DOCNO>NCT03041116</DOCNO>
	<brief_summary>This study investigate whether fosmetpantotenate ( RE-024 ) , phosphopantothenate replacement therapy , safe effective treating patient Pantothenate Kinase-Associated Neurodegeneration ( PKAN ) .</brief_summary>
	<brief_title>Efficacy Safety Study Fosmetpantotenate ( RE-024 ) PKAN Patients</brief_title>
	<detailed_description />
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
	<criteria>1 . The patient diagnosis PKAN indicate confirmed mutation pantothenate kinase 2 ( PANK2 ) gene . 2 . The patient male female age 6 65 year , inclusive . 3 . The patient score &gt; 6 PKANspecific activity daily live measure ( PKANADL ) 1 . The patient require regular intermittent invasive ventilatory support maintain vital sign within 24 week prior randomization . 2 . The patient deep brain stimulation ( DBS ) device implant within 6 month prior screen . 3 . The patient take deferiprone within 30 day prior screen . 4 . The patient unable maintain stable dos allow concomitant medication first 24 week study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PKAN</keyword>
</DOC>